The Company's strategy is to become a leader in the emerging field of pharmacogenomics, the science of individualizing therapy based on genetic differences across patients. Visible Genetics' genotyping technology, which employs DNA sequencing, enables the analysis, in the clinical diagnostic laboratory, of individual genetic variations.
Revenues reflect lower sale of sequencing systems.
Higher loss reflect higher payroll and personnel expenses, and the costs related to the opening of the Atlanta facility. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.